These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10622041)

  • 1. Efavirenz: practicalities, considerations and new issues.
    Moyle G
    Int J Clin Pract Suppl; 1999 Jun; 103():30-4. PubMed ID: 10622041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of NNRTIs: 'today and tomorrow'.
    Katlama C
    Int J Clin Pract Suppl; 1999 Jun; 103():16-20. PubMed ID: 10622038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new HAART on the horizon says the proof is in the potency.
    AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz-associated breast hypertrophy in HIV-infection patients.
    Mercié P; Viallard JF; Thiébaut R; Faure I; Rispal P; Leng B; Pellegrin JL
    AIDS; 2001 Jan; 15(1):126-9. PubMed ID: 11192857
    [No Abstract]   [Full Text] [Related]  

  • 5. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
    Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
    J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
    Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
    Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efavirenz-associated gynecomastia: report of five cases and review of the literature.
    Jover F; Cuadrado JM; Roig P; Rodríguez M; Andreu L; Merino J
    Breast J; 2004; 10(3):244-6. PubMed ID: 15125753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
    Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
    N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemolytic anaemia associated with efavirenz.
    Freercks RJ; Mehta U; Stead DF; Meintjes GA
    AIDS; 2006 May; 20(8):1212-3. PubMed ID: 16691081
    [No Abstract]   [Full Text] [Related]  

  • 12. Efavirenz and retinal toxicity.
    Lewis A; Mitchell S
    Eye (Lond); 2002 Jan; 16(1):107. PubMed ID: 11913879
    [No Abstract]   [Full Text] [Related]  

  • 13. Burning mouth syndrome due to efavirenz therapy.
    Borrás-Blasco J; Belda A; Rosique-Robles JD; Casterá MD; Abad FJ
    Ann Pharmacother; 2006; 40(7-8):1471-2. PubMed ID: 16822896
    [No Abstract]   [Full Text] [Related]  

  • 14. Switching from protease inhibitors to the non-nuke efavirenz.
    TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
    [No Abstract]   [Full Text] [Related]  

  • 15. Retinal toxicity due to Efavirenz.
    Curi AL; Freeman G; Kapembwa M; Pavesio C
    Eye (Lond); 2001 Apr; 15(Pt 2):246-8. PubMed ID: 11339611
    [No Abstract]   [Full Text] [Related]  

  • 16. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
    N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypersensitivity syndrome associated with efavirenz therapy.
    Bossi P; Colin D; Bricaire F; Caumes E
    Clin Infect Dis; 2000 Jan; 30(1):227-8. PubMed ID: 10619772
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV-related neutropaenia exacerbated by efavirenz.
    Healy BJ; Freedman AR
    HIV Med; 2006 Mar; 7(2):129-31. PubMed ID: 16420258
    [No Abstract]   [Full Text] [Related]  

  • 19. NNRTI hypersusceptibility.
    Delgado J; Shulman N
    AIDS Read; 2005 Jan; 15(1):28-30, 32-4. PubMed ID: 15685732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efavirenz].
    Taéron C
    Rev Infirm; 2005 May; (111):37-8. PubMed ID: 15991644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.